Abstract
Initial studies of vinorelbine (Navelbine®) given as a single agent to patients with operable non-small-cell lung cancer (NSCLC) showed that overall response rates of the order of 30% could be obtained with a schedule of 30 mg/m2 given weekly. Although such high levels of response have seldom been obtained when vinorelbine is given alone in one arm of a comparative study, the level of activity is clearly worthwhile and represents a significant improvement over supportive care. Combination therapy with cisplatin has been highly successful, establishing Vinorelbine as a safe well-tolerated agent which provides considerable activity, and experience from large phase III studies suggests that the combination of vinorelbine and cisplatin could represent a reference schedule against which other therapy should be compared.
Original language | English (US) |
---|---|
Pages (from-to) | S41-S45 |
Journal | Annals of Oncology |
Volume | 10 |
Issue number | SUPPL. 5 |
DOIs | |
State | Published - 1999 |
Externally published | Yes |
Keywords
- Cisplatin
- Non-small-cell lung cancer
- Vinorelbine
ASJC Scopus subject areas
- Hematology
- Oncology